伊沙妥昔单抗联合卡非佐米-地塞米松对比卡非佐米-地塞米松治疗复发多发性骨髓瘤患者(IKEMA研究):一项3期随机对照试验的总生存期分析
IKEMA研究为前瞻性随机开放标签3期试验,纳入302例复发或难治多发性骨髓瘤患者,按3:2随机接受伊沙妥昔单抗联合卡非佐米-地塞米松(伊沙妥昔单抗组179例)或卡非佐米-地塞米松(对照组123例)。中位随访56.61个月时,两组总生存期未检测到差异,伊沙妥昔单抗组中位总生存期未达到(95%CI 52.17-未达到),对照组为50.60个月(38.93-未达到),HR 0.855(95%CI 0.608-1.202),名义单侧p=0.18。
要点
- 伊沙妥昔单抗组中位总生存期未达到,对照组为50.60个月,HR 0.855(95%CI 0.608-1.202),未达统计学显著。
- 48个月生存概率伊沙妥昔单抗组59.7%(95%CI 52.0-66.7),对照组52.2%(95%CI 42.7-60.8)。
- 至下次治疗时间HR 0.583(95%CI 0.429-0.792),名义单侧p=0.0002,伊沙妥昔单抗组改善。
核心结论
- 本次分析时,两组间未检测到总生存期差异,且未观察到新的安全性信号。
- 证据总体提示伊沙妥昔单抗联合卡非佐米-地塞米松是复发或难治多发性骨髓瘤患者的关键治疗。
研究设计与样本
- 前瞻性、随机、开放标签、活性对照3期研究,纳入18岁及以上、既往接受1-3线治疗的复发或难治多发性骨髓瘤患者。
- 来自北美、南美、欧洲和亚太地区16个国家69个研究中心,共302例患者按3:2随机分配至伊沙妥昔单抗组(179例,59%)或对照组(123例,41%)。
- 伊沙妥昔单抗组接受静脉伊沙妥昔单抗10 mg/kg(首个28天周期第1、8、15、22天,后续28天周期第1、15天)。
- 两组均接受静脉卡非佐米(首周期第1、2天20 mg/m2;首周期第8、9、15、16天及后续周期第1、2、8、9、15、16天56 mg/m2)和静脉或口服地塞米松20 mg(第1、2、8、9、15、16、22、23天)。
- 主要终点为无进展生存期(已报告),本次总生存期分析计划在主要无进展生存期分析后3年于意向治疗人群中进行。
主要发现
- 截至2023年2月7日数据截止,伊沙妥昔单抗组发生79例(44%)总生存事件,对照组59例(48%),中位随访56.61个月(IQR 54.90-58.02)。
- 中位总生存期伊沙妥昔单抗组未达到(95%CI 52.17-未达到),对照组50.60个月(38.93-未达到),HR 0.855(95%CI 0.608-1.202),名义单侧p=0.18。
- 48个月生存概率伊沙妥昔单抗组59.7%(95%CI 52.0-66.7),对照组52.2%(95%CI 42.7-60.8),基于Kaplan-Meier分析。
- 至下次治疗时间HR 0.583(95%CI 0.429-0.792),名义单侧p=0.0002;第二次无进展生存期HR 0.663(95%CI 0.491-0.895),名义单侧p=0.0035,伊沙妥昔单抗组均观察到改善。
- 最常见治疗中出现的不良事件为输注反应(伊沙妥昔单抗组82例[46%],对照组4例[3%])和上呼吸道感染(分别为71例[40%]和34例[28%])。
关键数值与推荐
- 总生存期:伊沙妥昔单抗组未达到(95%CI 52.17-未达到)vs 对照组50.60个月(38.93-未达到),HR 0.855(95%CI 0.608-1.202),名义单侧p=0.18。
- 48个月生存概率:伊沙妥昔单抗组59.7%(95%CI 52.0-66.7)vs 对照组52.2%(95%CI 42.7-60.8)。
- 至下次治疗时间:HR 0.583(95%CI 0.429-0.792),名义单侧p=0.0002,伊沙妥昔单抗组改善。
- 第二次无进展生存期:HR 0.663(95%CI 0.491-0.895),名义单侧p=0.0035,伊沙妥昔单抗组改善。
- 因治疗中出现的不良事件而终止治疗:伊沙妥昔单抗组24例(14%)vs 对照组22例(18%),尽管伊沙妥昔单抗组暴露时间多30周。
临床怎么用
- 本次分析时两组间未检测到总生存期差异,且未观察到新的安全性信号。
- 证据总体提示伊沙妥昔单抗联合卡非佐米-地塞米松是复发或难治多发性骨髓瘤患者的关键治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Isatuximab is an anti-CD38 monoclonal antibody approved for the treatment of relapsed or refractory multiple myeloma. Previous analyses of the IKEMA trial showed prolonged progression-free survival in patients with this disease who received isatuximab in combination with carfilzomib-dexamethasone as compared with those who received carfilzomib-dexamethasone alone. Herein, we report the analysis of overall survival from the IKEMA trial. METHODS: This prospective, randomised, open-label, active-controlled, phase 3 study included patients with relapsed or refractory multiple myeloma aged 18 years or older, who had received one to three previous lines of treatment from 69 study centres in 16 countries across North America, South America, Europe, and the Asia-Pacific region. Patients were randomly allocated (3:2) to treatment with either isatuximab plus carfilzomib-dexamethasone (isatuximab group) or carfilzomib-dexamethasone (control group). In the isatuximab group, patients received intravenous isatuximab (10 mg/kg on days 1, 8, 15, and 22 of the first 28-day cycle, and days 1 and 15 of subsequent 28-day cycles). In both treatment groups, intravenous carfilzomib (20 mg/m2 on days 1 and 2 of the first cycle; and 56 mg/m2 on days 8, 9, 15, and 16 of the first cycle, and days 1, 2, 8, 9, 15, and 16 of subsequent cycles) and intravenous or oral dexamethasone (20 mg on days 1, 2, 8, 9, 15, 16, 22, and 23) were administered. The primary endpoint of the trial was progression-free survival, which was reported previously. Treatment continued until progression, unacceptable toxicity, or patient request to discontine. The overall survival analysis reported here was planned to be conducted 3 years after the primary progression-free survival analysis in the intention-to-treat population. Additional analyses were conducted on the secondary endpoints of time to next treatment and second-progression-free survival. Reported p values are non-inferential due to hierarchical testing. This trial is registered with ClinicalTrials.gov (NCT03275285). FINDINGS: Between Nov 15, 2017, and March 21, 2019, 302 patients were enrolled and randomly allocated: 179 (59%) to the isatuximab group and 123 (41%) to the control group. 169 (56%) patients were male, 133 (44%) were female, 214 (71%) were White, 50 (17%) were Asian, nine (3%) were Black or African American, and three (1%) were multiracial. At data cutoff for this overall survival analysis (Feb 7, 2023), 79 (44%) overall survival events in the isatuximab group and 59 (48%) in the control group had occurred (median follow-up 56·61 months [IQR 54·90-58·02]). Median overall survival (in months) was not reached (NR; 95% CI 52·17-NR) in the isatuximab group and was 50·60 months (38·93-NR) in the control group (hazard ratio [HR] 0·855 [95% CI 0·608-1·202], nominal one-sided p=0·18). Survival probability at 48 months was 59·7% (95% CI 52·0-66·7) in the isatuximab group and 52·2% (95% CI 42·7-60·8) in the control group (based on Kaplan-Meier analysis). Improvements in time to next treatment (HR 0·583 [95% CI 0·429-0·792], nominal one-sided p=0·0002) and second-progression-free survival (0·663 [0·491-0·895], nominal one-sided p=0·0035) were observed in the isatuximab group. The most common treatment-emergent adverse events were infusion reactions (82 [46%] patients in the isatuximab group and four [3%] in the control group) and upper respiratory tract infections (71 [40%] and 34 [28%], respectively). Discontinuations due to treatment-emergent adverse events were similar between treatment groups (24 [14%] in the isatuximab group and 22 [18%] in the control group), despite an additional 30 weeks of exposure in the isatuximab group. 12 (7%) patients in the isatuximab group and six (5%) patients in the control group had a treatment-related adverse event with a fatal outcome during study treatment. INTERPRETATION: At the time of the current analysis, a difference in overall survival could not be detected between the treatment groups, and no new safety signals were observed. Collectively, the evidence suggests that isatuximab plus carfilzomib-dexamethasone is a key treatment for patients with relapsed or refractory multiple myeloma. FUNDING: Sanofi.
引用
- Yong K, Martin T, Dimopoulos MA, et al. Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial. Lancet Haematol. 2024. PMID: 39067465. doi:10.1016/S2352-3026(24)00148-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。